EFOMP Malaga Declaration 2023: An updated vision on Medical Physics in Europe

Byrne, Brenda; Marcu, Loredana G.; Mazzoni, Lorenzo Nicola; Caruana, Carmel J.; Barry, Amanda; Martin, Graham D.; Stasi, M.; Ruíz, Simón; Medina, Antonio López; Platoni, Kalliopi; Maas, Ad J.J.; Agius, Sam; Koutsouveli, Efi; Gilligan, Paddy

doi:10.1016/j.ejmp.2023.102620

Cited by 6 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this point, we reinforce in particular hybrid systems such as MR-LINAC and PET-MR, radiomics, artificial intelligence and multi-modal imaging. These topics represent important fields of research and development in oncology clinical trials, as evidenced by numerous recently published articles, including some position papers from international scientific societies [180][181][182][183][184][185][186][187][188][189][190][191][192][193][194][195][196][197][198][199]. The second is that it was not possible to follow a rigorous selection criterion to include the articles, given the high number of manuscripts published in recent years on QIBs.…”

Section: Discussionmentioning

confidence: 99%

A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation

Chauvie,

Mazzoni,

O’Doherty

2023

Tomography

Self Cite

View full text Add to dashboard Cite

Imaging biomarkers (IBs) have been proposed in medical literature that exploit images in a quantitative way, going beyond the visual assessment by an imaging physician. These IBs can be used in the diagnosis, prognosis, and response assessment of several pathologies and are very often used for patient management pathways. In this respect, IBs to be used in clinical practice and clinical trials have a requirement to be precise, accurate, and reproducible. Due to limitations in imaging technology, an error can be associated with their value when considering the entire imaging chain, from data acquisition to data reconstruction and subsequent analysis. From this point of view, the use of IBs in clinical trials requires a broadening of the concept of quality assurance and this can be a challenge for the responsible medical physics experts (MPEs). Within this manuscript, we describe the concept of an IB, examine some examples of IBs currently employed in clinical practice/clinical trials and analyze the procedure that should be carried out to achieve better accuracy and reproducibility in their use. We anticipate that this narrative review, written by the components of the EFOMP working group on “the role of the MPEs in clinical trials”-imaging sub-group, can represent a valid reference material for MPEs approaching the subject.

show abstract

Section: Discussionmentioning

confidence: 99%

A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation

Chauvie,

Mazzoni,

O’Doherty

2023

Tomography

Self Cite

View full text Add to dashboard Cite

show abstract

“…The MPE can 'act or give advice on patient dosimetry, the development and use of complex techniques and equipment, on optimisation, on quality assurance and quality control, and on other matters relating to RP' (definition adapted from Directive [34]) so their 'key role is applying ALARA for patient and staff ' both in IR and NM. As a result 'fewer MPEs means less optimisation' and EFOMP aspires to promote and define a harmonised role and set of responsibilities of the MPE, but experience [8], survey [25] and discussion [32] show that the MPE E&T, role and responsibilities all vary among countries and are not always aligned with the EFOMP Malaga statement [34]-a benchmark for the role, E&T and responsibilities of the MPE. The absence of MPE input in the development and introduction of new radiopharmaceuticals [12] and of radiopharmacy design has been repeatedly highlighted [12,20,32].…”

Section: Roles Of the Different Partiesmentioning

confidence: 99%

Synthesis of the European ALARA network 20th workshop ‘ALARA for interventional radiology and nuclear medicine’

Andresz,

Allisy-Roberts,

Economides

et al. 2024

J. Radiol. Prot.

View full text Add to dashboard Cite

The European ALARA Network regularly organises workshops on topical issues in radiation protection. The topic of the 20th workshop was: “ALARA for interventional radiology (IR) and nuclear medicine (NM)”. The main objective was to examine the challenges faced when applying the optimisation principle (ALARA) in IR and NM and to consider how ALARA could be better implemented for patient and staff exposures. This memorandum provides a synthesis of the workshop sessions and recommendations arising from the working groups discussion. Parallels are drawn with the recommendations coming from the 13th EAN workshop on “ALARA and the medical sector” (2011) to consider how the optimisation challenges in IR and NM have evolved over the past decade.Current levels of exposure are presented along with operational practice and the challenges and opportunities for improvement, both in monitoring and practice. Whilst RP challenges remain, the application of ALARA appears more established in IR compared with experiences reported in 2011. The application of ALARA to emerging technologies in the NM setting is in need of further development to ensure that radiation protection is considered at all stages in the development process of new radiopharmaceuticals. Besides technical and operational aspects, the importance of education and training, human factors and , broadly, the radiation protection ‘culture’ were deemed fundamental to the success of the application of ALARA and where further emphasis is needed. All concerned parties, MPEs, RPEs, medical staff, manufacturers and regulators have a role to play in the application of ALARA and this is discussed in the memorandum. Many of the recommendations from the 13th EAN workshop remain applicable today and overlap with the recommendations arising from the 20th workshop. This should prompt attention given that the use of IR and the development of novel radiopharmaceuticals for NM is only anticipated to increase with time.

show abstract

EFOMP policy statement 18: Medical physics education for the non-physics healthcare professions

et al. 2023

View full text Add to dashboard Cite

EFOMP Malaga Declaration 2023: An updated vision on Medical Physics in Europe

Cited by 6 publications

References 2 publications

A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation

A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation

Synthesis of the European ALARA network 20th workshop ‘ALARA for interventional radiology and nuclear medicine’

EFOMP policy statement 18: Medical physics education for the non-physics healthcare professions

Contact Info

Product

Resources

About